1. Introduction
Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disorder that currently plagues five million Americans. AD can be broadly classified into either familial or sporadic forms of the disease. Familial cases result from genetic mutations in amyloid precursor protein (APP) and proteins involved in APP processing, including presenilin 1 (PS1) and presenilin 2 (PS2) (Rocchi et al., 2003; Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 1995) . However, the vast majority (>90%) of AD cases are of the sporadic variety. A well-established genetic risk factor for sporadic AD is apolipoprotein E (ApoE), specifically its ApoE4 isoform. ApoE4 has been the subject of extensive research because individuals that are homozygous for the ApoE4 allele have a high incidence of developing sporadic AD (Corder et al., 1993; Strittmatter and Roses, 1996) . Clinical AD diagnosis occurs when multiple symptoms including memory impairment, aphasia, apraxia, agnosia, and general loss of executive functions, are manifested in the individual and collectively contribute to dementia not due to other causes (Association, 2000) . It is interesting to note that these symptoms also arise in the reverse order of which they are acquired throughout childhood development (Reisberg et al., 1986) .
On a molecular level AD is characterized by the accumulation of senile plaques (SP), which are predominately composed of the short amyloid b-peptide (Ab), and neurofibrillary tangles (NFT), which are composed largely of hyperphosphorylated tau protein. The 40 and 42 amino acid peptides of Ab are prevalent in SP of AD patients. Both SPs and NFTs are formed in the hippocampus and neocortical regions of the brain. Molecular confirmation of the clinical diagnosis of AD is made post-mortem based upon criteria such as the number of senile plaques and neurofibrillary tangles (Mirra et al., 1991) and by Braakstage scoring (Braak and Braak, 1991) .
SPs and NFTs, together with synapse loss, are the classical pathological hallmarks of AD. The exact mechanisms accounting for these pathological hallmarks and their contribution to the clinical symptoms associated with the disease are not yet fully understood. Using the knowledge of genetic mutations that result in familial AD and the association of sporadic AD with the ApoE4 allele (see Table 1 ), several rodent models have been developed to aid in the elucidation of AD pathogenesis. The risk of developing neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) increases with age. AD and PD are the two most common neurodegenerative diseases that currently affect millions of persons within the United States population. While many clues about the mechanisms of these disorders have been uncovered, to date, the molecular mechanisms associated with the cause of these diseases are not completely understood. Furthermore, there are no available cures or preventive treatments for either disorder. Animal models of AD and PD, though not perfect, offer a means to gain knowledge of the basic biochemistry associated with these disorders and with drug efficacy. The field of proteomics which focuses on identifying the dynamic nature of the protein content expressed within a particular cell, tissue, or organism, has provided many insights into these disturbing disorders. Proteomic studies have revealed many pathways that are associated with disease pathogenesis and that may lead to the development of potential therapeutic targets. This review provides a discussion of key findings from AD and PD proteomics-based studies in various animal models of disease.
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